Failure of combination therapy for Staphylococcus aureus bone infection: a case of in vivo selection with resistance to rifampicin and fusidic acid

Infect Dis (Lond). 2016 Sep;48(9):699-702. doi: 10.1080/23744235.2016.1183815. Epub 2016 May 19.

Abstract

Staphylococcus aureus is one of the main etiologies of bone and device-related infections. Treatment of these orthopedic infections combines mostly rifampicin with other antibiotics. The recurrence or failure rate after fusidic acid/rifampicin treatment remains low (<10%). We discuss here a case of antibiotic treatment failure for Staphylococcus aureus bone infection with in vivo selection of rifampicin and fusidic acid resistance. We also report a new mutation in fusA gene involved in fusidic acid resistance.

Keywords: Biofilm; Staphylococcus aureus; bone; fusA; resistance; rpoB.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Bone Diseases, Infectious* / drug therapy
  • Bone Diseases, Infectious* / microbiology
  • Drug Resistance, Bacterial / genetics
  • Fusidic Acid* / pharmacology
  • Fusidic Acid* / therapeutic use
  • Humans
  • Male
  • Rifampin* / pharmacology
  • Rifampin* / therapeutic use
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus* / drug effects
  • Staphylococcus aureus* / genetics

Substances

  • Anti-Bacterial Agents
  • Fusidic Acid
  • Rifampin